Prevalence of FLEDR and TRAELDT in patients with SSc divided by clinical subtypes.

a<p>adjusted standardized residual >1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true (represented in bold), with a significance level of.05. An adjusted residual < −2.0 indicates that the number of cases in that cell is significantly smaller than would be expected if the null hypothesis were true (represented in italic).</p>b<p>when comparing different subgroups for FLEDR association: DcSSc/LcSSc/healthy controls: χ² = 29.1, p<10⁻⁵; LcSSc/healthy controls: not significant; DcSSc/healthy controls: χ² = 28.4, p<10⁻⁶.</p>c<p>when comparing different subgroups for TRAELDT association: DcSSc/LcSSc/healthy controls: χ² = 10.2, p = 0.029; LcSSc/healthy controls: not significant; DcSSc/healthy controls: χ² = 7.2, p = 0.027.</p

Prevalence of FLEDR and TRAELDT in patients with SSc divided by antibody status.

a<p>adjusted standardized residual >1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true (represented in bold), with a significance level of.05. An adjusted residual < −2.0 indicates that the number of cases in that cell is significantly smaller than would be expected if the null hypothesis were true (represented in italic).</p>b<p>when comparing different subgroups for FLEDR association: Ab neg/ACA pos/ATA pos/healthy controls: χ² = 48.5, p<10⁻⁸; Ab neg/healthy controls: not significant; ACA pos/healthy controls: χ² = 0.17, p = 0.9; ATA pos: χ² = 43.9, p<10⁻⁹.</p>c<p>when comparing different subgroups for TRAELDT association: Ab neg/ACA pos/ATA pos/healthy controls: χ² = 27.6, p = 0.00013; Ab neg/healthy controls: not significant; ACA pos: χ² = 7.9, p = 0.02; ATA pos/healthy controls: χ² = 14.6, p = 0.0007.</p

Shared amino acid sequences of the most common DRß chains.

<p>Shared amino acid sequences of the most common DRß chains.</p

mRNA expression of DRB5*01 and DRB1*15 in patients with SSc and controls (CTL).

<p>mRNA expression of DRB5*01 and DRB1*15 in patients with SSc and controls (CTL).</p